It is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.
June 2016
As the end of my hematology/oncology fellowship draws near, I am reminded every day that oncology is not about winning or losing.
Through this eventful journey, I have experienced stark contrasts.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5